Skip to main content
Midas Edge

Raphael Pharmaceutical Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

RAPHStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

Common stock · Additional paid-in · Accumulated · Total
Number · Amount · capital · deficit · equity
Balance as of January 1, 202418,502,918$185$7,392$(7,310)$267
Issuance of common stock and warrants158,5002178-180
Net loss---(550)(550)
Balance as of March 31, 202418,661,418$187$7,570$(7,860)$(103)
Issuance of common stock in exchange for services40,000(*)61-61
Net loss---(248)(248)
Balance as of June 30, 202418,701,418187$7,631$(8,108)$(290)
Net loss(326)(326)
Balance as of September 30, 202418,701,4181877,631(8,434)(616)
Common stock · Additional paid-in · Accumulated · Total
NumberAmountcapitaldeficitequity
Balance as of January 1, 202518,701,418$187$7,960$(8,889)$(742)
Issuance of common stock and warrants575,0006234-240
Share based compensation350,0003194197
Net loss---(429)(429)
Balance as of March 31, 202519,626,418$196$8,388$(9,318)$(734)
Share based compensation8-8
Net loss---(322)(322)
Balance as of June 30, 202519,626,418196$8,396$(9,640)$(1,048)
Share based compensation39-39
Net loss---(255)(255)
Balance as of September 30, 202519,626,4181968,435(9,895)(1,264)
(*)Less than 1 thousand.

-F-3-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.